Lingaiah, S., Morin-Papunen, L., Piltonen, T., Puurunen, J., Sundström-Poromaa, I., Stener-Victorin, E., … Tapanainen, J. S. (2017). Bone markers in polycystic ovary syndrome: A multicentre study. Clinical Endocrinology, 87(6), 673–679. https://doi.org/10.1111/cen.13456
Bone markers in polycystic ovary syndrome : a multicentre study
|Author:||Lingaiah, Shilpa1; Morin‐Papunen, Laure1; Piltonen, Terhi1;|
1Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Centre, Oulu University Hospital and University of Oulu, Oulu, Finland
2Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden
3Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
4Medical Informatics and Statistics Research Group, University of Oulu, Oulu, Finland
5Department of Clinical Chemistry, Oulu University Hospital, Oulu, Finland
6Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 0.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019082725783
John Wiley & Sons,
|Publish Date:|| 2019-08-27
Objective: Hyperandrogenism, hyperinsulinaemia and obesity, known characteristics of polycystic ovary syndrome (PCOS), may influence bone mineral density and biochemical markers of bone turnover (BTMs) can provide a noninvasive assessment of bone turnover. To this end, the serum concentrations of BTMs and 25‐hydroxyvitamin D (25OHD) were analysed in women with PCOS, and their possible associations with metabolic parameters of PCOS were determined.
Subjects and methods: Bone formation markers procollagen type I amino‐terminal propeptide (PINP) and osteocalcin (OC), and bone resorption marker carboxy‐terminal cross‐linking telopeptide of type I collagen (CTX), along with 25OHD, were measured in 298 women with PCOS and 194 healthy controls.
Results: Serum levels of PINP (47.0 ± 20.2 vs 58.1 ± 28.6 μg/L, P < .001) and OC (18.2 ± 7.5 vs 20.6 ± 9.8 μg/L, P < .001) were decreased in women with PCOS compared with controls, whereas no significant differences were found in CTX and 25OHD levels. Age‐stratified analyses suggested that PINP (50.5 ± 21.7 vs 68.2 ± 26.6 μg/L, P < .001) and OC levels (20.4 ± 7.6 vs 25.5 ± 9.6 μg/L,P < .001) were decreased only in the younger age group (≤30 years) women with PCOS compared with controls. The formation markers and resorption marker decreased with age in both study groups.
Conclusions: Bone formation markers were decreased in younger women with PCOS when compared with healthy women, which may affect bone mass in these women.
|Pages:||673 - 679|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
This work was supported by grants from the Sigrid Jusélius Foundation, the Academy of Finland, Medical Research Centre Oulu, Oulu University Hospital and University of Oulu, the Oulu University Scholarship Foundation, the Jalmari and Rauha Ahokas Foundation and Nordlab, Oulu University Hospital. The authors thank Katja Koukkula for skilful technical assistance and Nick Bolton for revision of language.
© 2017 John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Lingaiah, S., Morin-Papunen, L., Piltonen, T., Puurunen, J., Sundström-Poromaa, I., Stener-Victorin, E., … Tapanainen, J. S. (2017). Bone markers in polycystic ovary syndrome: A multicentre study. Clinical Endocrinology, 87(6), 673–679. https://doi.org/10.1111/cen.13456, which has been published in final form at https://doi.org/10.1111/cen.13456. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.